食道がん化学放射線療法における病期,奏効と予後との相関

概要

論文の詳細を見る
The association of disease stage and response with survival following treatment with 5-fluorouracil/cisplatin-based chemoradiotherapy (CRT) was evaluated in 51 Japanese patients with esophageal squamous cell carcinoma (ESCC). One course of treatment consisted of protracted venous infusions of 5-fluorouracil (400mg/m^2/24h for days 1-5 and 8-12) and cisplatin (40mg/m^2/3h on day 1 and 8), and radiation (2Gy/day on days 1-5, 8-12 and 15-19), and a 2nd course was given after a 2-week interval. The response was assessed about 4 weeks after the CRT by endoscopy, and chest and abdominal CT scans. The CR+PR rate was 80%, which was consistent with other institutions, and we confirmed that this CRT procedure was effective even for Stage III ESCC. The 2-year survival rate was 52%, which was comparable with or better than other institutions. Our results also showed that survival depended on the disease stage (p=0.027, Log-rank test). The response (CR or non-CR) was also associated with survival (p<0.0001, Log-rank test) with 2-year survival rates of 88% and 13% for CR patients and non-CR patients, respectively. Overall, we concluded that the prognosis could be predicted from the disease stage or response, hopefully with good accuracy.
日本医療薬学会の論文
2008-01-10